Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reduced-dose Chemotherapy Followed by Blinatumomab in Newly Diagnosed Ph- B-ALL
NCT05557110Phase 2Completed
- Start
- Sep 2022
- Primary completion
- Jan 2024
- Modality
- Antibody Conjugates, scFv Fragments, Bispecific Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of blinatumomab in B cell acute lymphoblastic leukemia (B-ALL). Started Sep 2022; status: completed.
02
Drugs
blinatumomab
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NCT05557110.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05557110.